• Explore /
  • Poster
  • / Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).

Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).

Abstract Poster

Authors

Jeffrey Jones

Jeffrey Alan Jones

The Ohio State University Comprehensive Cancer Center, Columbus, OH

Jeffrey Alan Jones , Tadeusz Robak , Malgorzata Wach , Jennifer R. Brown , Alexander R. Menter , Elizabeth Vandenberghe , Loic Ysebaert , Nina D. Wagner-Johnston , Jonathan Polikoff , Farrukh Tauseef Awan , Xavier Camille Albert Badoux , Steven Coutre , Stephen Edward Forbes Spurgeon , Javier Loscertales , Lyndah Dreiling , Guan Xing , Sissy Peterman , Ronald L. Dubowy , Ian Flinn , Carolyn Owen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT01659021

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7515)

DOI

10.1200/JCO.2016.34.15_suppl.7515

Abstract #

7515

Poster Bd #

71

Abstract Disclosures

Similar Posters

First Author: Ian Flinn

First Author: Jennifer R. Brown

First Author: Jacqueline Claudia Barrientos

First Author: Wojciech Jurczak